10.6084/m9.figshare.4653838.v1
Park J.S.
Park
J.S.
Rha S.Y.
Rha
S.Y.
Chung H.C.
Chung
H.C.
Jung M.
Jung
M.
Kim K.H.
Kim
K.H.
Jun H.J.
Jun
H.J.
Kim H.
Kim
H.
An J.Y.
An
J.Y.
Kim H.-I.
Kim
H.-I.
Cheong J.-H.
Cheong
J.-H.
Hyung W.J.
Hyung
W.J.
Noh S.H.
Noh
S.H.
Kim H.S.
Kim
H.S.
Supplementary Material for: Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
Karger Publishers
2017
Gastric cancer
HER
Predictive factor
Chemotherapy
2017-02-15 14:52:46
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Clinicopathological_Features_and_Prognostic_Significance_of_HER2_Expression_in_Gastric_Cancer/4653838
<p><b><i>Background:</i></b> HER2 positivity is reported to be <20%
in gastric cancer. Clinicopathological characteristics will be helpful
to understand the biological features of HER2-positive gastric cancer. <b><i>Methods:</i></b>
A total of 813 gastric cancer patients who underwent HER2 testing
between January 2005 and December 2010 were included in this study. <b><i>Results:</i></b>
Ninety-five (11.7%) patients had HER2-positive gastric cancer. Elevated
serum carcinoembryonic antigen (CEA) concentration [odds ratio (OR),
5.629; p < 0.001] and differentiated histology (OR, 3.717; p = 0.002)
were significant predictive factors for HER2 positivity in localized
disease. For recurrent or metastatic disease, elevated serum CEA
concentration (OR, 2.545; p < 0.001), differentiated histology (OR,
3.299; p < 0.001), pulmonary metastasis (OR, 3.321; p = 0.001), and
distant lymph node metastasis (OR, 2.286; p = 0.002) were significant
predictive factors. Median disease-free survival (DFS) was shorter in
HER2-positive patients than in others, especially in stage I or II
disease (24.7 vs. 49.2 months; p < 0.001). Among HER2-negative
patients with stage II diseases, patients who received adjuvant
chemotherapy had longer DFS than others (42.2 vs. 30.7 months; p =
0.025). <b><i>Conclusions:</i></b> Clinicopathological factors may be
useful in predicting the HER2 positivity of gastric cancer. Further
studies are needed to understand the molecular basis of HER2-positive
gastric cancer. </p>